These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23285908)

  • 81. Hospital pharmacists' knowledge and opinions regarding adverse drug reaction reporting in Northern China.
    Su C; Ji H; Su Y
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):217-22. PubMed ID: 20033911
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Adverse reaction induced by licorice preparations: clinical analysis of 93 cases].
    Mao M; Li W; Wang W; Wang SX; Lu J; Chang ZF
    Zhongguo Zhong Yao Za Zhi; 2013 Nov; 38(21):3768-72. PubMed ID: 24494570
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Research progress of Chinese herbal medicine and traditional Chinese medicine resulting in liver injury].
    Wang J; Zhou C
    Zhongguo Zhong Yao Za Zhi; 2011 Dec; 36(23):3371-4. PubMed ID: 22393753
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Chinese herbal medicine for cancer pain.
    Xu L; Lao LX; Ge A; Yu S; Li J; Mansky PJ
    Integr Cancer Ther; 2007 Sep; 6(3):208-34. PubMed ID: 17761635
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Future development of global regulations of Chinese herbal products.
    Fan TP; Deal G; Koo HL; Rees D; Sun H; Chen S; Dou JH; Makarov VG; Pozharitskaya ON; Shikov AN; Kim YS; Huang YT; Chang YS; Jia W; Dias A; Wong VC; Chan K
    J Ethnopharmacol; 2012 Apr; 140(3):568-86. PubMed ID: 22373513
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A Retrospective Analysis on 1330 Adverse Event Reports of Qingkailing in China: Further Perception of Its Risks and Rational Use.
    Wu BL; He WX; Ke M; Shang-Guan XF; He GF; Huang R
    Curr Med Sci; 2018 Dec; 38(6):1103-1108. PubMed ID: 30536076
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Literature metrology analysis of adverse reactions reports of Denzhanxixin injection].
    Li YY; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2789-91. PubMed ID: 23285935
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Closed-loop management model of clinical investigational product for new drug of traditional Chinese medicine].
    Wu P; Zhang JW
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(17):2898-900. PubMed ID: 24380320
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Role of traditional Chinese medicine injection infusion with precise infusion apparatus].
    Han HM; Zhi YJ
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2758-9. PubMed ID: 23285928
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Study of post marketing safety reevaluation of shenqi fuzheng injection].
    Ai QH; Li YY; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3633-6. PubMed ID: 25532410
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Advance in studies on hongsheng dan].
    Chen H; Zhu Y
    Zhongguo Zhong Yao Za Zhi; 2012 Mar; 37(6):746-9. PubMed ID: 22715714
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Major achievements of evidence-based traditional Chinese medicine in treating major diseases.
    Chao J; Dai Y; Verpoorte R; Lam W; Cheng YC; Pao LH; Zhang W; Chen S
    Biochem Pharmacol; 2017 Sep; 139():94-104. PubMed ID: 28636884
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Expert consensus on the design and implementation of clinical safety centralized monitoring study of Chinese medical injection].
    Zhang JH; Ren JT; Hu JQ; Xie YM; Song HB; Zhu MJ; Gao R; Wang Z; Zheng WK; Li XL; Jiang M; Huang YH; Lu F; He LY; Lian WX; Yang ZQ; Yuan WA; Hu SY; Wang BH; Wang WL; Ren DQ; Zhang BL; ;
    Zhongguo Zhong Yao Za Zhi; 2017 Jan; 42(1):6-9. PubMed ID: 28945018
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Technical specifications for hospital-based intensive monitoring of post-marketing Chinese patent medicine].
    Xie YM; Liao X; Jiang JJ; Zhang YL; Ma R; Zhu MJ; Zhan SY; Liu JP; Liu J; Wen ZH; Yang ZQ; He Y; Li XL
    Zhongguo Zhong Yao Za Zhi; 2019 Jul; 44(14):2896-2901. PubMed ID: 31602831
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Discussion on adverse reactions monitoring modes of drug manufacturers under new measures for administration of adverse drug reaction report and monitoring].
    Yang YY; Dong Z; Xia YP
    Zhongguo Zhong Yao Za Zhi; 2012 Nov; 37(21):3329-33. PubMed ID: 23397739
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Analysis of clinical safety for Shenmai injection based on literature].
    Wang LX; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2779-81. PubMed ID: 23285932
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Expert consensus post-marketing evaluation scheme to detect immunotoxicity of Chinese medicine in clinical populations (draft version for comments)].
    Xie YM; Zhao YB; Jiang JJ; Chang YP; Zhang W; Shen H; Lu PF
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2933-6. PubMed ID: 24471307
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Security revaluation study based on nested case-control method of Danhong injection].
    Li CX; Tang JF; Meng F; Li XL
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2735-8. PubMed ID: 23285922
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Risk control system construction of Shenfu injection].
    Tian DL; Li K; Jiang JJ; Zhu YN
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2814-7. PubMed ID: 23285942
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Reporting traditional Chinese medicine morbidity--A University of Technology, Sydney, project with an emphasis on developing standards for testing and reporting data.
    Meier PC; Rogers C
    J Altern Complement Med; 2006; 12(6):529-34. PubMed ID: 16884343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.